Skip to content
Screener

Insulet PODD Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$10.69B+246%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$34.63M-265%
Medtronic logo
MedtronicMDT
$2.57B+1.8%
Beta Bionics logo
Beta BionicsBBNX
-$14.62M-7.6%
Embecta Corp. logo
Embecta Corp.EMBC
$31.1M-2.2%
Opko Health logo
Opko HealthOPK
-$43.5M+47.9%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions)Six Months Ended / 2026Six Months Ended / 2025
Prepaid expenses and other assets(28.1)(31.6)
Accounts payable39.972.6
Accrued expenses and other liabilities5.618.7
Net cash provided by operating activities202.2260.3
Cash flows from investing activities
Capital expenditures(56.8)(30.9)
Investments in developed software(8.3)(8.0)
Net cash used in investing activities(65.1)(38.9)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's operating cash flow?
Insulet (PODD) reported operating cash flow of $88.4M in Q2 2026.
How has Insulet's operating cash flow changed year-over-year?
Insulet's operating cash flow decreased by 55.0% year-over-year, from $196.5M to $88.4M.
What is the long-term trend for Insulet's operating cash flow?
Over 3 years (2022 to 2025), Insulet's operating cash flow has grown at a 68.5% compound annual growth rate (CAGR), from $119M to $569.3M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Insulet's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude